Mereo Bio fast tracked for lung disease

 esignation Validates Alvelestat’s Potential to Address a Serious Unmet Need

Company Plans R&D Update on Alvelestat in AATD-associated Lung Disease on October 31, 2022

 Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its investigational oral neutrophil elastase inhibitor, alvelestat (MPH-966). Mereo intends to have an End-of-Phase 2 meeting with the FDA to discuss the design of a registration-enabling study for alvelestat as a treatment for AATD-associated lung disease, including the potential opportunity for an accelerated approval pathway, around the end of the year.

https://finance.yahoo.com/news/mereo-biopharma-receives-fda-fast-110000347.html